Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

NTLA

Intellia Therapeutics (NTLA)

Intellia Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:NTLA
DateTimeSourceHeadlineSymbolCompany
01/12/202208:36GlobeNewswire Inc.Intellia Therapeutics Announces Proposed Public Offering of Common StockNASDAQ:NTLAIntellia Therapeutics Inc
15/11/202208:35TipRanksChardan Capital Sticks to Their Buy Rating for Intellia Therapeutics (NTLA)NASDAQ:NTLAIntellia Therapeutics Inc
15/11/202201:45TipRanksIntellia Therapeutics (NTLA) Receives a Hold from BMO CapitalNASDAQ:NTLAIntellia Therapeutics Inc
14/11/202223:31Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:NTLAIntellia Therapeutics Inc
13/11/202208:30GlobeNewswire Inc.Intellia Therapeutics Presents New Interim Data from First-in-Human Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the American College of Allergy, Asthma & Immunology 2022 Annual Scientific MeetingNASDAQ:NTLAIntellia Therapeutics Inc
10/11/202215:27TipRanksSVB Securities Sticks to Their Buy Rating for Intellia Therapeutics (NTLA)NASDAQ:NTLAIntellia Therapeutics Inc
10/11/202215:21TipRanksAnalysts Have Conflicting Sentiments on These Healthcare Companies: Biogen (BIIB), BioMarin Pharmaceutical (BMRN) and Intellia Therapeutics (NTLA)NASDAQ:NTLAIntellia Therapeutics Inc
08/11/202208:43Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:NTLAIntellia Therapeutics Inc
08/11/202208:10TipRanksAnalysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), Quest Diagnostics (DGX) and Intellia Therapeutics (NTLA)NASDAQ:NTLAIntellia Therapeutics Inc
07/11/202214:35TipRanksSVB Securities Keeps Their Buy Rating on Intellia Therapeutics (NTLA)NASDAQ:NTLAIntellia Therapeutics Inc
06/11/202207:00GlobeNewswire Inc.Intellia Presents Updated Interim Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis at the American Heart Association Scientific Sessions 2022NASDAQ:NTLAIntellia Therapeutics Inc
05/11/202201:01TipRanksAnalysts Have Conflicting Sentiments on These Healthcare Companies: Amgen (AMGN), Fate Therapeutics (FATE) and Intellia Therapeutics (NTLA)NASDAQ:NTLAIntellia Therapeutics Inc
04/11/202223:17TipRanksJ.P. Morgan Keeps Their Buy Rating on Intellia Therapeutics (NTLA)NASDAQ:NTLAIntellia Therapeutics Inc
04/11/202216:05TipRanksIntellia Therapeutics (NTLA) Receives a Buy from JMP SecuritiesNASDAQ:NTLAIntellia Therapeutics Inc
04/11/202209:25TipRanksChardan Capital Remains a Buy on Intellia Therapeutics (NTLA)NASDAQ:NTLAIntellia Therapeutics Inc
04/11/202207:05Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:NTLAIntellia Therapeutics Inc
03/11/202222:41Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:NTLAIntellia Therapeutics Inc
03/11/202222:30GlobeNewswire Inc.Intellia Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Recent Company ProgressNASDAQ:NTLAIntellia Therapeutics Inc
31/10/202222:30GlobeNewswire Inc.Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema at the 2022 ACAAI Annual Scientific MeetingNASDAQ:NTLAIntellia Therapeutics Inc
27/10/202222:30GlobeNewswire Inc.Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2022 Earnings and Company UpdatesNASDAQ:NTLAIntellia Therapeutics Inc
26/09/202221:30GlobeNewswire Inc.Intellia Therapeutics to Present at October Healthcare Investor ConferencesNASDAQ:NTLAIntellia Therapeutics Inc
19/09/202222:45TipRanksIntellia Therapeutics (NTLA) Receives a Buy from SVB SecuritiesNASDAQ:NTLAIntellia Therapeutics Inc
17/09/202207:05TipRanksIntellia Therapeutics (NTLA) Receives a Buy from Chardan CapitalNASDAQ:NTLAIntellia Therapeutics Inc
17/09/202206:05TipRanksJMP Securities Remains a Buy on Intellia Therapeutics (NTLA)NASDAQ:NTLAIntellia Therapeutics Inc
17/09/202201:58TipRanksPiper surprised by Intellia selloff, says data ‘checks all boxes’NASDAQ:NTLAIntellia Therapeutics Inc
16/09/202222:22TipRanksIntellia Therapeutics (NASDAQ: NTLA) Jumps After Positive Clinical DataNASDAQ:NTLAIntellia Therapeutics Inc
16/09/202221:37Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:NTLAIntellia Therapeutics Inc
16/09/202221:15GlobeNewswire Inc.Intellia and Regeneron Announce Initial Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) AmyloidosisNASDAQ:NTLAIntellia Therapeutics Inc
16/09/202221:15PR Newswire (US)Intellia and Regeneron Announce Initial Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) AmyloidosisNASDAQ:NTLAIntellia Therapeutics Inc
16/09/202221:00GlobeNewswire Inc.Intellia Therapeutics Announces Positive Interim Clinical Data for its Second Systemically Delivered Investigational CRISPR Candidate, NTLA-2002 for the Treatment of Hereditary Angioedema (HAE)NASDAQ:NTLAIntellia Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:NTLA